The MarketReader Minute
IBB is trading higher from Friday’s close as investors position ahead of the AACR26 Annual Meeting (Apr 17–22). Gains in RVMD, IQV, ILMN, VRTX, and ALNY are supporting the move, despite macro pressure from rising oil prices tied to renewed U.S.-Iran tensions.
The MarketReader Minute
IBB rose nearly 2% as gains in Amgen, Moderna, and Vertex lifted the sector, with easing geopolitical tensions and falling oil prices supporting risk sentiment.
The MarketReader Minute
IBB edged lower as declines in Gilead, Amgen, and Regeneron weighed on the sector, extending recent weakness despite broader strength in health insurers following the Medicare Advantage rate update.
The MarketReader Minute
IBB rose over 4% as biotech rallied on renewed M&A momentum, led by Eli Lilly's agreement to acquire Centessa. Gains across holdings including Apellis, Regeneron, Moderna and Gilead supported the move, reflecting improved sentiment in the sector.
The MarketReader Minute
The iShares Biotechnology ETF (IBB) rose nearly 1% as gains in Vertex Pharmaceuticals, United Therapeutics, and Regeneron supported the sector despite broader market pressure.
The MarketReader Minute
The iShares Biotechnology ETF (IBB) fell about 0.4%, with losses across holdings including IQVIA, MannKind, Biogen, Waters, and Cytokinetics weighing on performance. The decline comes alongside a modest drop in the Russell 2000, reflecting softer sentiment toward biotech and small-cap growth stocks.
The MarketReader Minute
Biotech stocks moved higher, with (IBB) rising about 0.6% as expectations for increased pharmaceutical dealmaking and investment supported sentiment. Gains in Vertex, Moderna, Sarepta, IQVIA, and Iovance helped lift the sector alongside strength in small-cap equities.
The MarketReader Minute
Biotechnology stocks moved modestly higher, lifting the iShares Biotechnology ETF (IBB) by about 0.9% despite recent weekly declines across the sector. Gains in key holdings including Regeneron, Vaxcyte, Gilead, Amgen, and Twist Bioscience supported performance.
The MarketReader Minute
(IBB) rose 0.8% as positive regulatory developments and supportive macro data boosted sector sentiment. ImmunityBio’s ANKTIVA received approval from the Saudi Food and Drug Authority. Gains among major holdings, including Gilead, Amgen, Moderna, Incyte, and Sarepta, further supported the ETF.
The MarketReader Minute
(IBB) declined 0.6% Tuesday amid broad market volatility tied to weaker labor data. Sarepta Therapeutics led losses, offsetting stronger revenue results. Additional pressure came from Regeneron, Moderna, Alnylam, and Myriad Genetics, as investors weighed mixed earnings and macroeconomic uncertainty.
The MarketReader Minute
IBB fell 0.7% since Friday on heavy trading volume, even as it remains up 8.25% YTD and posted a 3.55% weekly gain. Regeneron slipped despite positive Phase 3 antibody trial data, while Moderna and BioNTech declined on lung cancer trial updates.
The MarketReader Minute
IBB advanced with notable contributions from Cytokinetics, Ionis, and Biogen, supported by fresh approvals and positive clinical data. Eupraxia’s trial news added momentum, offsetting recent weekly weakness and lifting year-to-date gains to 4.6%.
